Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform trial of long-acting antibodies for moderately to severely active ulcerative colitis
2025-521242-26-00Phase 2Authorised
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 38
01
Overview
Phase 2, randomised, double-blind trial of SPY001, SPY002 and SPY003 in autoimmune colitis (7 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoints: Change in RHI from baseline at Week 12 (Part A) and Clinical remission at Week 12 (Part B). Planned start Nov 2025; status: authorised.
02
Drugs
SPY001SPY002SPY003
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-521242-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521242-26-00.